Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Standard care or no added treatment Metformin	metformin titrated over 3 weeks to 1000 mg twice daily; lifestyle: standard	14	11
A2	Liraglutide 1.8 mg subcutaneous once daily Metformin and liraglutide	metformin 1000 mg twice daily; lifestyle: standard	11	10

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Standard care or no added treatment A1	Liraglutide 1.8 mg subcutaneous once daily A2
age	mean (years)	15.6	15.0
age	sd (years)	2.1	2.1
asian	n	0	0
black	n	13	11
bmi	mean (kg/m2)	39.4	38.2
bmi	sd (kg/m2)	7.9	8.0
diabetes duration	mean (years)	1.5	1.0
female	n	7	7
female	percent	50	64
hba1c	mean (percent)	6.4	7.4
hba1c	sd (percent)	0.7	0.9
other race american indian alaska native	n	0	0
other race multiple	n	0	0
other race native hawaiian pacific islander	n	0	0
sbp	mean (mmHg)	131	128
sbp	sd (mmHg)	14	14
weight	mean (kg)	116.2	113.3
weight	sd (kg)	25.3	23.3
white	n	0	0

Analyses this trial contributes to

HbA1c change
Children and adolescents with type 2 diabetes; weeks 12 to 40 (target week 26); network meta-analysis
HbA1c change
Children and adolescents with type 2 diabetes; weeks 12 to 40 (target week 26); descriptive only
Level 2 or 3 hypoglycemia (participants)
Children and adolescents with type 2 diabetes; longest follow-up; descriptive only
Level 2 or 3 hypoglycemia (participants)
Children and adolescents with type 2 diabetes; longest follow-up; descriptive only
Serious adverse events
Children and adolescents with type 2 diabetes; longest follow-up; descriptive only
Serious adverse events
Children and adolescents with type 2 diabetes; longest follow-up; network meta-analysis
Nausea
Children and adolescents with type 2 diabetes; longest follow-up; network meta-analysis
Nausea
Children and adolescents with type 2 diabetes; longest follow-up; descriptive only
Vomiting
Children and adolescents with type 2 diabetes; longest follow-up; descriptive only
Vomiting
Children and adolescents with type 2 diabetes; longest follow-up; network meta-analysis
Diarrhea
Children and adolescents with type 2 diabetes; longest follow-up; descriptive only
Diarrhea
Children and adolescents with type 2 diabetes; longest follow-up; network meta-analysis

Results

12 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

HbA1c change (2 lines; O01)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
12	A1	final	47.1 mmol/mol		39.4 to 54.7		not stated; per protocol; R0019860:Table 1
12	A2	final	50.0 mmol/mol		34.2 to 65.8		not stated; per protocol; R0019860:Table 1

Level 2 or 3 hypoglycemia (participants) (2 lines; O04)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				1 / 13	not stated; safety; registry:adverse_events
	A2	events				3 / 11	not stated; safety; registry:adverse_events

Serious adverse events (2 lines; O25)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				0 / 13	not stated; safety; registry:adverse_events
	A2	events				0 / 11	not stated; safety; registry:adverse_events

Nausea (2 lines; O27A)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				1 / 13	not stated; safety; registry:adverse_events
	A2	events				1 / 11	not stated; safety; registry:adverse_events

Vomiting (2 lines; O27B)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				0 / 13	not stated; safety; registry:adverse_events
	A2	events				3 / 11	not stated; safety; registry:adverse_events

Diarrhea (2 lines; O27C)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				2 / 13	not stated; safety; registry:adverse_events
	A2	events				2 / 11	not stated; safety; registry:adverse_events

NCT02960659

Design

Conduct and analysis

Arms

Baseline characteristics

Analyses this trial contributes to

Results